Product Description
KUR-101 is being developed by Kures for the treatment of acute pain. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05114265?term=KUR-101&draw=2&rank=1)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Kures
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: New Zealand
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Acute Pain
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| KUR-101-101 | P1 |
Completed |
Acute Pain |
2022-10-12 |
43% |